세계의 피브린 실란트 시장 : 제형별, 용도별, 최종 사용자별 기회 분석 및 산업 예측(2021-2031년)

Fibrin sealants are used in a wide range of surgeries, primarily as hemostatic agents, however, also to assist tissue sealing and wound healing. Fibrin sealants are used during surgeries to avoid surgical complications such as air and fluid leaks. These sealants are available in the form of films, powder and liquid, and aid by creating a hemostatic layer, which stops blood and air leakage from the targeted area.

Fibrin sealants contain fibrinogen and thrombin, they differ in their final composition. This affects properties of the resulting fibrin clot and may influence their use in different surgical procedures. Fibrin sealants with high concentrations of fibrinogen tend to produce stronger clots, whereas those containing higher concentrations of thrombin form clots rapidly.

Major factors driving growth of the fibrin sealants market include rise in technological advancements, increase in prevalence rate of chronic diseases such as heart diseases, cancer, ischemic stroke, aneurysm, and increase in road accidents propel high adoption of fibrin sealants for these surgeries.

For instance, according to World Health Organization Cardiovascular diseases (CVDs) are leading cause of death globally, taking an estimated 17.9 million lives each year. It has been estimated in 2020 that around 17.9 million people die each year from CVDs, an estimated 31% of all deaths worldwide. For instance, according to the National Center for Health Statistics, every year, about 805,000 people in the U.S. have a heart attack. This led to increase in number cardiac surgeries and use of fibrin sealants.

However, unfavorable reimbursements as well as complications such as high costs associated with fibrin sealant products are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for fibrin sealant manufacturers worldwide in the future.

Furthermore, healthcare business is projected to witness growth, owing to rise in surgeries such heart bypass surgery, cancer surgeries, solid tumor surgeries, neurothrombectomy, organ transplant surgeries, increase in R&D investments in discovery & development of advanced fibrin sealants, and rise in awareness regarding use of fibrin sealants for reducing blood loss in surgeries. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The fibrin sealants market is segmented on the basis of dosage form, application, end user, and region. On the basis of dosage form, the market is classified into liquid, patch, and powder. On the basis of application, it is classified into general surgery, cardiovascular surgery, wound management, orthopedic surgery, urological surgeries, ophthalmic surgeries, and others. Depending on end user, it is fragmented into hospitals, ambulatory surgical centers, and clinics. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Baxter International Inc., Becton, Dickinson and Company, Corza Medical, CSL Behring, Grifols, S.A., Hemarus Therapeutics Ltd, Johnson and Johnson, Nordson Corporation (Nordson Medical), Shanghai RAAS Blood Products Co., Ltd., and Vivostat A/S.

KEY BENEFITS FOR STAKEHOLDERS

• This report provides an extensive analysis of the current and emerging market trends and dynamics in the fibrin sealants market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across various regions.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region & country wise analysis is provided to understand the market trends and dynamics.

Key Market Segments

By Dosage Forms

• Liquid
• Patch
• Powder

By Application

• General Surgery
• Cardiovascular Surgery
• Wound Management
• Orthopedic Surgery
• Urological Surgeries
• Ophthalmic Surgeries
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics

By Region

• North America
  • Canada
  • Mexico
  • U.S.
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
• Key Market Players
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Corza Medical
  • CSL Behring
  • Grifols
  • hemarus therapeutics ltd.
  • Johnson and Johnson
  • Nordson Corporation (Nordson Medical)
  • Shanghai RAAS Blood Products Co., Ltd.
  • vivostat a/s

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: FIBRIN SEALANTS MARKET, BY DOSAGE FORMS

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Liquid
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Patch
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Powder
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country

CHAPTER 5: FIBRIN SEALANTS MARKET, BY APPLICATION

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 General Surgery
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Cardiovascular Surgery
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Wound Management
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country
• 5.5 Orthopedic Surgery
  • 5.5.1 Key market trends, growth factors and opportunities
  • 5.5.2 Market size and forecast, by region
  • 5.5.3 Market analysis by country
• 5.6 Urological Surgeries
  • 5.6.1 Key market trends, growth factors and opportunities
  • 5.6.2 Market size and forecast, by region
  • 5.6.3 Market analysis by country
• 5.7 Ophthalmic Surgeries
  • 5.7.1 Key market trends, growth factors and opportunities
  • 5.7.2 Market size and forecast, by region
  • 5.7.3 Market analysis by country
• 5.8 Others
  • 5.8.1 Key market trends, growth factors and opportunities
  • 5.8.2 Market size and forecast, by region
  • 5.8.3 Market analysis by country

CHAPTER 6: FIBRIN SEALANTS MARKET, BY END USER

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospitals
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Ambulatory Surgical Centers
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
• 6.4 Clinics
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country

CHAPTER 7: FIBRIN SEALANTS MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Dosage Forms
  • 7.2.3 North America Market size and forecast, by Application
  • 7.2.4 North America Market size and forecast, by End User
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Dosage Forms
    • 7.2.5.1.2 Market size and forecast, by Application
    • 7.2.5.1.3 Market size and forecast, by End User
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Dosage Forms
    • 7.2.5.2.2 Market size and forecast, by Application
    • 7.2.5.2.3 Market size and forecast, by End User
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Dosage Forms
    • 7.2.5.3.2 Market size and forecast, by Application
    • 7.2.5.3.3 Market size and forecast, by End User
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Dosage Forms
  • 7.3.3 Europe Market size and forecast, by Application
  • 7.3.4 Europe Market size and forecast, by End User
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Dosage Forms
    • 7.3.5.1.2 Market size and forecast, by Application
    • 7.3.5.1.3 Market size and forecast, by End User
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Dosage Forms
    • 7.3.5.2.2 Market size and forecast, by Application
    • 7.3.5.2.3 Market size and forecast, by End User
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Dosage Forms
    • 7.3.5.3.2 Market size and forecast, by Application
    • 7.3.5.3.3 Market size and forecast, by End User
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Dosage Forms
    • 7.3.5.4.2 Market size and forecast, by Application
    • 7.3.5.4.3 Market size and forecast, by End User
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Dosage Forms
    • 7.3.5.5.2 Market size and forecast, by Application
    • 7.3.5.5.3 Market size and forecast, by End User
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Dosage Forms
    • 7.3.5.6.2 Market size and forecast, by Application
    • 7.3.5.6.3 Market size and forecast, by End User
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Dosage Forms
  • 7.4.3 Asia-Pacific Market size and forecast, by Application
  • 7.4.4 Asia-Pacific Market size and forecast, by End User
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Dosage Forms
    • 7.4.5.1.2 Market size and forecast, by Application
    • 7.4.5.1.3 Market size and forecast, by End User
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Dosage Forms
    • 7.4.5.2.2 Market size and forecast, by Application
    • 7.4.5.2.3 Market size and forecast, by End User
    • 7.4.5.3 India
    • 7.4.5.3.1 Market size and forecast, by Dosage Forms
    • 7.4.5.3.2 Market size and forecast, by Application
    • 7.4.5.3.3 Market size and forecast, by End User
    • 7.4.5.4 Australia
    • 7.4.5.4.1 Market size and forecast, by Dosage Forms
    • 7.4.5.4.2 Market size and forecast, by Application
    • 7.4.5.4.3 Market size and forecast, by End User
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Dosage Forms
    • 7.4.5.5.2 Market size and forecast, by Application
    • 7.4.5.5.3 Market size and forecast, by End User
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Dosage Forms
    • 7.4.5.6.2 Market size and forecast, by Application
    • 7.4.5.6.3 Market size and forecast, by End User
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Dosage Forms
  • 7.5.3 LAMEA Market size and forecast, by Application
  • 7.5.4 LAMEA Market size and forecast, by End User
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Dosage Forms
    • 7.5.5.1.2 Market size and forecast, by Application
    • 7.5.5.1.3 Market size and forecast, by End User
    • 7.5.5.2 South Africa
    • 7.5.5.2.1 Market size and forecast, by Dosage Forms
    • 7.5.5.2.2 Market size and forecast, by Application
    • 7.5.5.2.3 Market size and forecast, by End User
    • 7.5.5.3 Saudi Arabia
    • 7.5.5.3.1 Market size and forecast, by Dosage Forms
    • 7.5.5.3.2 Market size and forecast, by Application
    • 7.5.5.3.3 Market size and forecast, by End User
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Dosage Forms
    • 7.5.5.4.2 Market size and forecast, by Application
    • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Baxter International Inc.
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Becton, Dickinson and Company
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Corza Medical
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 CSL Behring
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Grifols
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 hemarus therapeutics ltd.
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Johnson and Johnson
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Nordson Corporation (Nordson Medical)
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Shanghai RAAS Blood Products Co., Ltd.
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 vivostat a/s
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments